PTLF (Petlife Pharmaceuticals) ROCE %: 0.00% (As of Feb. 2018)


What is Petlife Pharmaceuticals ROCE %?

Petlife Pharmaceuticals PTLF ROCE % is 0.00% as of Feb. 2018.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Petlife Pharmaceuticals's annualized ROCE % for the quarter that ended in Feb. 2018 was 0.00%.

Petlife Pharmaceuticals  (OTCPK:PTLF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Petlife Pharmaceuticals ROCE % Related Terms

Petlife Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals ROCE % Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -8,894.12 0.00 0.00 0.00

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Petlife Pharmaceuticals ROCE % Calculation

Petlife Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Aug. 2017 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Aug. 2017 )  (A: Aug. 2016 )(A: Aug. 2017 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Aug. 2017 )  (A: Aug. 2016 )(A: Aug. 2017 )
=-22.873/( ( (0.001 - 3.236) + (0.055 - 1.436) )/ 2 )
=-22.873/( (-3.235+-1.381)/ 2 )
=-22.873/-2.308
=991.03 %

Petlife Pharmaceuticals's ROCE % of for the quarter that ended in Feb. 2018 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Feb. 2018 )  (Q: Nov. 2017 )(Q: Feb. 2018 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Feb. 2018 )  (Q: Nov. 2017 )(Q: Feb. 2018 )
=-1.532/( ( (0.058 - 1.83) + (0.008 - 1.981) )/ 2 )
=-1.532/( ( -1.772 + -1.973 )/ 2 )
=-1.532/-1.8725
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2018) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Petlife Pharmaceuticals (PTLF) has a ROCE % of 0.00% as of Feb. 2018.
Is Petlife Pharmaceuticals' ROCE % too high?
Petlife Pharmaceuticals' current ROCE % is 0.00%.
How does Petlife Pharmaceuticals' ROCE % compare to PCYN and YBAO?
Petlife Pharmaceuticals' ROCE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petlife Pharmaceuticals's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current ROCE % is 0.00% as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.